Literature DB >> 10071343

Immunodeficiency-associated lymphoproliferative disorders.

D M Knowles1.   

Abstract

The incidence of lymphoproliferative disease is significantly higher in individuals who have congenital, acquired, or iatrogenically induced immunodeficiency. The immunodeficiency-associated lymphoproliferative disorders are clinically and pathologically heterogeneous, are of variable clonal composition, and vary according to the immunodeficiency syndrome. Nonetheless, they share several features, including frequent origination in or involvement of extranodal sites, diffuse aggressive histology, B-cell lineage derivation, association with the Epstein-Barr virus (EBV), and, often, rapid clinical progression. Reactive and atypical lymphoid hyperplasias and malignant lymphomas occur in association with congenital (primary) immunodeficiency. Post-transplantation lymphoproliferative disorders are often comprised of a polymorphic cell population, making it difficult to identify their benign or malignant nature by histopathologic criteria alone. Recent studies suggest that they are divisible into plasmacytic hyperplasias, polymorphic lymphoproliferative disorders, and malignant lymphomas. The plasmacytic hyperplasias are polyclonal and generally regress spontaneously following withdrawal of immunosuppression. The malignant lymphomas are monoclonal, possess a variety of genetic alterations, and generally progress despite aggressive therapy. The polymorphic lymphoproliferative disorders are also monoclonal but display variable clinical behavior, their progression apparently correlating with bcl-6 gene mutation. Non-Hodgkin's lymphoma (NHL) is the second most common AIDS-related neoplasm and an AIDS-defining illness. AIDS-related NHLs are divisible by anatomic site of origin into systemic (nodal/extra nodal), primary central nervous system, and body cavity-based (primary effusion) lymphomas; and by histopathology into Burkitt's and Burkitt's-like lymphoma, large cell lymphoma, and large cell immunoblastic (plasmacytoid) lymphoma More than 90% are monoclonal B-cell neoplasms. The primary effusion lymphomas contain the Kaposi's sarcoma-associated herpesvirus. Multiple molecular pathways appear to operate in AIDS lymphomagenesis and some may be preferentially associated with specific histopathologic categories or anatomic sites of origin. In conclusion, the immunodeficiency-associated lymphoproliferative disorders often represent a significant diagnostic problem requiring correlative analysis of the clinical behavior of the patient with the histopathology, immunophenotype, clonal composition, viral content, and genetic alterations of the lymphoproliferative disorder. They also represent an important biological model for studying the development and progression of lymphoid neoplasia

Entities:  

Mesh:

Year:  1999        PMID: 10071343

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  25 in total

1.  [Current aspects of the therapy with topical calcineurin inhibitors].

Authors:  E Enderlein; S Meller; J Rieker; T Ruzicka; B Homey
Journal:  Hautarzt       Date:  2005-10       Impact factor: 0.751

Review 2.  Primary cutaneous plasmacytoma after rejection of a transplanted kidney: case report and review of the literature.

Authors:  Gianpaolo Tessari; Fabio Fabbian; Chiara Colato; Fabio Benedetti; Massimo Franchini; Vittorio Ortalda; Lucia Cavallini; Annalisa Barba
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

3.  Methotrexate-related Epstein-Barr Virus (EBV)-associated lymphoproliferative disorder--so-called "Hodgkin-like lesion"--of the oral cavity in a patient with rheumatoid arthritis.

Authors:  Kentaro Kikuchi; Yuji Miyazaki; Akio Tanaka; Hisao Shigematu; Masaru Kojima; Hideaki Sakashita; Kaoru Kusama
Journal:  Head Neck Pathol       Date:  2010-07-31

4.  An Epstein-Barr virus mutant produces immunogenic defective particles devoid of viral DNA.

Authors:  Sophia Pavlova; Regina Feederle; Kathrin Gärtner; Walter Fuchs; Harald Granzow; Henri-Jacques Delecluse
Journal:  J Virol       Date:  2012-12-12       Impact factor: 5.103

Review 5.  [Primary CNS lymphoma in azathioprine therapy for autoimmune diseases: review of the literature and case report].

Authors:  F Kästner; W Paulus; M Deckert; P Schlegel; S Evers; I W Husstedt
Journal:  Nervenarzt       Date:  2007-04       Impact factor: 1.214

Review 6.  [Aggressive primary cutaneous B-cell lymphomas and novel EBV+ entities].

Authors:  C Lamos; E Dippel
Journal:  Hautarzt       Date:  2017-09       Impact factor: 0.751

7.  Polymorphous lymphoproliferative disorder: a clinicopathological analysis.

Authors:  Naoto Nakamichi; Naoki Wada; Masaharu Kohara; Shirou Fukuhara; Haruo Sugiyama; Hiroyasu Ogawa; Masayuki Hino; Akihisa Kanamaru; Yuzuru Kanakura; Eiichi Morii; Katsuyuki Aozasa
Journal:  Virchows Arch       Date:  2010-01-29       Impact factor: 4.064

8.  Epstein-Barr virus-negative diffuse large B-cell lymphoma hosts intra- and peritumoral B-cells with activated Epstein-Barr virus.

Authors:  Christiane Stuhlmann-Laeisz; Monika Szczepanowski; Alisa Borchert; Monika Brüggemann; Wolfram Klapper
Journal:  Virchows Arch       Date:  2014-10-23       Impact factor: 4.064

9.  Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study.

Authors:  Nathalie Berghen; Laure-Anne Teuwen; Rene Westhovens; Patrick Verschueren
Journal:  Clin Rheumatol       Date:  2015-07-30       Impact factor: 2.980

10.  Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.

Authors:  Ola Landgren; Ethel S Gilbert; J Douglas Rizzo; Gérard Socié; Peter M Banks; Kathleen A Sobocinski; Mary M Horowitz; Elaine S Jaffe; Douglas W Kingma; Lois B Travis; Mary E Flowers; Paul J Martin; H Joachim Deeg; Rochelle E Curtis
Journal:  Blood       Date:  2009-03-05       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.